Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03623854 · ClinicalTrials.gov registry record · Phase 2
Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03623854 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 10 participants.
The verdict
NCT03623854, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase II trial studies how well nivolumab and relatlimab work in treating participants with chordoma that has spread to other places in the body. Monoclonal antibodies, such as nivolumab and relatlimab, may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Relatlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-04-03 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03623854
The ClinicalTrials.gov registry entry for NCT03623854 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03623854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03623854 about?
NCT03623854 is a clinical study titled "Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma". This phase II trial studies how well nivolumab and relatlimab work in treating participants with chordoma that has spread to other places in the body. Monoclonal antibodies, such as nivolumab and relatlimab, may interfere with the ability of tumor cells to grow and spread.
What is the current status of trial NCT03623854?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-04-03. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT03623854?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Relatlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03623854?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.